Glucoryl MV 1 mg Tablet

• Type 2 diabetes mellitus

Glucoryl MV 1 mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

• Nausea
• Diarrhea
• Abdominal pain
• Hypoglycemia (low blood glucose level)
• Loss of appetite

Seek medical attention in case of any unusual or severe side effects immediately.

• Take Glucoryl MV 1 Tablet in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition.
• This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.
  
  

• Glucoryl MV 1 mg Tablet is an anti-diabetic medicine. It is a combination of Glimepiride (1mg), Metformin (500mg) and Voglibose (0.2mg). As a sulfonylurea, glimepiride minimizes blood sugar by stimulating the pancreas to secrete more insulin.
• Metformin is a biguanide that increases the body's tolerance to insulin, reduces the liver's synthesis of glucose, and slows down the intestines' absorption of glucose.
• Alpha-glucosidase inhibitors like voglibose prevent complex sugars from breaking down into simple sugars like glucose. As a result, this medicine prevents blood glucose levels from rising to extremely high levels immediately after meals.
  

• Shamanna, P., Jha, P. K., Makwana, A., Shukla, H., & Bavishi, C. (2024). Observational, Multicenter, Retrospective, Study on the Usage Patterns of the Fixed Dose Combination of Glimepiride, Metformin, and Voglibose in Type 2 Diabetes Management. Cureus, 16(1). https://pubmed.ncbi.nlm.nih.gov/38348001/
• Nigam, N., Anand, P., Kumar, S., & Manchi, R. K. (2021). COMPARATIVE STUDY OF EFFICACY AND SAFETY OF METFORMIN+ GLIMEPIRIDEVSMETFORMIN+ GLIMEPIRIDE+ VOGLIBOSE IN TYPE 2 DIABETES MELLITUS PATIENTS AT TERTIARY CARE CENTRE, KANPUR. Journal of Advanced Scientific Research, 12(01 Suppl 2), 204-207. https://www.sciensage.info/index.php/JASR/article/view/1206
• Manjula, S. Expert perspectives on the use of a triple combination of voglibose, glimepiride and metformin for the management of diabetes in Indian settings. https://www.researchgate.net/publication/380524644_Expert_perspectives_on_the_use_of_a_triple_combination_of_voglibose_glimepiride_and_metformin_for_the_management_of_diabetes_in_Indian_settings
• Faruqui, A. A. (2016). Safety and efficacy of fixed dose combination of voglibose, glimepiride and metformin in Indian type 2 diabetes mellitus patients. Age (yrs), 36, 78. https://www.researchgate.net/publication/346988980_Safety_and_Efficacy_of_Fixed_Dose_Combination_of_Voglibose_Glimepiride_and_Metformin_in_Indian_Type_2_Diabetes_Mellitus_Patients
• BANTWAL, G., AYYAR, V., KOVIL, R., CHAWLA, M., SHAH, T., KUMAR, S., ... & REVANKAR, S. (2021). Assessment of Clinical Experience of Triple Drug Fixed-dose Combination of Glimepiride, Metformin and Voglibose in the Management of Type 2 Diabetes Mellitus: A Retrospective Study. Journal of Clinical & Diagnostic Research, 15(9). https://www.researchgate.net/publication/357481699_Assessment_of_Clinical_Experience_of_Triple_Drug_Fixed-dose_Combination_of_Glimepiride_Metformin_and_Voglibose_in_the_Management_of_Type_2_Diabetes_Mellitus_A_Retrospective_Study